Toxicological safety data requirements for many environmental chemicals, for example drugs, pesticides and food additives are so rigorous that it is difficult to believe that there are any to which man can readily be exposed that are not covered by some legislation or other. Such is the case, however, for there are a number of compounds which large numbers of people regularly ingest or apply to various parts of their anatomy which escape control. The case of Orobronze has recently been discussed in Drug and Therapeutics Bulletin (1983) . Containing the naturally occurring orange carotenoid canthaxanthin, it is available over the counter for oral ingestion as an artificial 'suntan' agent. Canthaxanthin is an approved food additive, having shown no toxic or carcinogenic effects, or adverse effects on reproduction in the usual animal tests, but no studies have been carried out of its routes of metabolism or of its long-term safety in man in doses taken for its cosmetic as distinct from its food additive use. Because no medicinal claims are made of it, Orobronze escapes the Medicines Act legislation and a product licence is not required for the DHSS.
A similar situation exists for products which are applied to the vagina but for which medicinal claims are not made, such as tampons which are still not subject to safety testing requirements despite the association of toxic shock syndrome with these devices (de Saxe et al., 1982) . Vaginal applications are widely available, and, although ostensibly cosmetic in purpose and so free from control under the Medicines Act, many contain potentially harmful ingredients. For example, a marketed douche powder, when dissolved according to the manufacturers instructions, would contain a final concentration of boric acid of about 0.8%, which is even above the Cosmetic Products Regulations (1978) limit of 0.5% for oral hygiene products. Boric acid is of doubtful therapeutic value, has known toxicological hazards, yet it is permitted in a preparation which will give it access to the vaginal mucosa, because under the Medicines Act, as in the Cosmetic Products Regulations, such local vaginal applications are treated as products for external, not internal use.
It is surely inappropriate that materials such as these should escape the safety net while such stringent demands are made for the testing of substances to which man is exposed in much smaller quantities or for greater benefit.
